Abstract
Background/Aim: In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro. However, whether amentoflavone augments anticancer efficacy of sorafenib in HCC in vivo is unknown. The aim of the present study was to verify the anticancer effect of amentoflavone combined with sorafenib in HCC in vivo. Materials and Methods: HCC SK-Hep1 tumor-bearing mice were treated with vehicle, sorafenib, amentoflavone, or combination for 14 days, respectively. Effect of sorafenib, amentoflavone, or their combination on tumor growth, anti-apoptotic potential, apoptotic signaling and general toxicity were evaluated with digital caliper, immunohistochemistry staining and body weight. Results: Our results demonstrated that amentoflavone significantly enhanced sorafenib-inhibited tumor growth and expression of ERK/AKT phosphorylation and anti-apoptotic proteins compared to single-agent treatment. Additionally, amentoflavone also triggered sorafenib-induced apoptosis through extrinsic and intrinsic apoptotic pathways. Conclusion: Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 2119-2125 |
| Number of pages | 7 |
| Journal | Anticancer Research |
| Volume | 38 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2018 |
Fingerprint
Keywords
- AKT
- Amentoflavone
- Apoptosis.
- ERK
- Hepatocellular carcinoma
- Sorafenib
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo. / Tsai, Jai Jen; Hsu, Fei Ting; Pan, Po Jung; Chen, Chia Wen; Kuo, Yu Cheng.
In: Anticancer Research, Vol. 38, No. 4, 01.04.2018, p. 2119-2125.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo
AU - Tsai, Jai Jen
AU - Hsu, Fei Ting
AU - Pan, Po Jung
AU - Chen, Chia Wen
AU - Kuo, Yu Cheng
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background/Aim: In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro. However, whether amentoflavone augments anticancer efficacy of sorafenib in HCC in vivo is unknown. The aim of the present study was to verify the anticancer effect of amentoflavone combined with sorafenib in HCC in vivo. Materials and Methods: HCC SK-Hep1 tumor-bearing mice were treated with vehicle, sorafenib, amentoflavone, or combination for 14 days, respectively. Effect of sorafenib, amentoflavone, or their combination on tumor growth, anti-apoptotic potential, apoptotic signaling and general toxicity were evaluated with digital caliper, immunohistochemistry staining and body weight. Results: Our results demonstrated that amentoflavone significantly enhanced sorafenib-inhibited tumor growth and expression of ERK/AKT phosphorylation and anti-apoptotic proteins compared to single-agent treatment. Additionally, amentoflavone also triggered sorafenib-induced apoptosis through extrinsic and intrinsic apoptotic pathways. Conclusion: Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.
AB - Background/Aim: In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro. However, whether amentoflavone augments anticancer efficacy of sorafenib in HCC in vivo is unknown. The aim of the present study was to verify the anticancer effect of amentoflavone combined with sorafenib in HCC in vivo. Materials and Methods: HCC SK-Hep1 tumor-bearing mice were treated with vehicle, sorafenib, amentoflavone, or combination for 14 days, respectively. Effect of sorafenib, amentoflavone, or their combination on tumor growth, anti-apoptotic potential, apoptotic signaling and general toxicity were evaluated with digital caliper, immunohistochemistry staining and body weight. Results: Our results demonstrated that amentoflavone significantly enhanced sorafenib-inhibited tumor growth and expression of ERK/AKT phosphorylation and anti-apoptotic proteins compared to single-agent treatment. Additionally, amentoflavone also triggered sorafenib-induced apoptosis through extrinsic and intrinsic apoptotic pathways. Conclusion: Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.
KW - AKT
KW - Amentoflavone
KW - Apoptosis.
KW - ERK
KW - Hepatocellular carcinoma
KW - Sorafenib
UR - http://www.scopus.com/inward/record.url?scp=85045207671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045207671&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12452
DO - 10.21873/anticanres.12452
M3 - Article
AN - SCOPUS:85045207671
VL - 38
SP - 2119
EP - 2125
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 4
ER -